Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 2, 2020

ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting

By Victoria Smith

Results from the Phase III ADAURA clinical trial were announced at the virtual ASCO 2020 conference on Sunday 31 May, highlighting significant improvements in both primary and secondary endpoints, leading to a new standard of care for a subgroup of non-small-cell lung cancer (NSCLC) patients.

Last month, the ADAURA trial was recommended by an Independent Data Monitoring Committee (IDMC) to be unblinded two years early after detailed results and overwhelming efficacy were presented at ASCO 2020 for the first time. Read more here.

Related Companies

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy